|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
|
Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f... |
|
|
Office Practice of Primary Care Medicine 2024 - LIVE STREAMING
The Comprehensive 2024 Update on Office-Based Primary Care Medicine
Taught Live Online by Harvard Medical School's Leading Clinical Faculty
Office Practice of Primary Care Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies.
OVERVIEW
Office Practice of Primary Care Medicine provides comprehensive reviews of the most important recent advances impacting primary care medicine and guidance to assimilate these changes... |
|
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate.
Program Overview
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing ... |
|
|
How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r... |
|
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |
|
|
The Critical Role of Managed Care Pharmacists in Optimizing Treatment of Iron Deficiency in Patients with Heart Failure
Despite evidence-based interventions to prevent or manage heart failure (HF), poor HF-related outcomes persist as evidenced by the number of preventable HF-related hospitalizations and high readmission rates. Moreover, the economic burden that HF places on the health care system is significant. Pharmacists can improve adherence to guideline recommendations for the use of intravenous (IV) iron therapy for patients with HF and iron deficiency (ID) and develop treatment pathways and implement for... |
|
|
Conquering Lab Interpretation (eLearning)
No matter what your area of expertise, no field in medicine spends enough time training you for lab interpretation. Join us as we conquer the interpretation of lab findings to help you gain the clues you need to provide better care to your patients. What we understand, we can then use to set up the plan of the day, to progress the patient towards good outcomes and to predict the next step in the treatment goal. Data collection and understanding are important steps in the development of critica... |
|
|
Conquering Lab Interpretation (DVD-ROM)
No matter what your area of expertise, no field in medicine spends enough time training you for lab interpretation. Join us as we conquer the interpretation of lab findings to help you gain the clues you need to provide better care to your patients. What we understand, we can then use to set up the plan of the day, to progress the patient towards good outcomes and to predict the next step in the treatment goal. Data collection and understanding are important steps in the development of critica... |
|
|
The latest insights into rare blood disorders: Diagnosis and treatment strategies
Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it is essential that healthcare providers possess up-to-date information about best practices... |
|
|
Unmasking Multiple Myeloma and Its Precursor Conditions in Primary Care
For multiple myeloma (MM) patients to receive the most appropriate care, a quick and accurate diagnosis is paramount. This is especially the case for Black patients, as diagnosis has historically been slower in Black patients"even though MM is twice as common in Black Americans than in White Americans. Additionally, MM precursor conditions such as monoclonal gammopathy of undetermined significance are seen more frequently in Black Americans than in White Americans. Primary care providers ... |
|